BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response

Yael Peled, Eilon Ram, Jacob Lavee, Leonid Sternik, Amit Segev, Anat Wieder-Finesod, Michal Mandelboim, Victoria Indenbaum, Itzchak Levy, Ehud Raanani, Yaniv Lustig, Galia Rahav

Research output: Contribution to journalArticlepeer-review

102 Scopus citations


Background: Data on the safety and efficacy of SARS-CoV-2 vaccines in immunocompromised populations are sparse. Methods: We conducted a prospective study of 77 heart transplant (HT) recipients vaccinated with two doses of BNT162b2 vaccine and monitored for adverse events following both doses, the receptor-binding domain (RBD) IgG response, and neutralizing antibodies. Results: BNT162b2 vaccination was associated with a low rate of adverse events, characterized mostly by pain at the injection site. By a mean 41 days post second dose there were no clinical episodes of rejection, as suggested by a troponin leak or allograft dysfunction. At a mean 21 days following the second dose, IgG anti-RBD antibodies were detectable in 14 (18%) HT recipients. Immune sera neutralized SARS-CoV-2 pseudo-virus in 8 (57%) of those with IgG anti-RBD antibodies. Immunosuppressive regimen containing mycophenolic acid was associated with lower odds of an antibody response (OR = 0.12, p = 0.042). Conclusions: Whether a longer time-frame for observation of an antibody response is required after vaccination in immunosuppressed individuals remains unknown.

Original languageEnglish
Pages (from-to)759-762
Number of pages4
JournalJournal of Heart and Lung Transplantation
Issue number8
StatePublished - Aug 2021
Externally publishedYes


  • BNT162b2 vaccine
  • antibody response
  • heart transplantation


Dive into the research topics of 'BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response'. Together they form a unique fingerprint.

Cite this